Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Atb Cap Markets lowered their FY2025 earnings per share estimates for Bradmer Pharmaceuticals in a research note issued on Sunday, March 30th. Atb Cap Markets analyst M. Toner now expects that the company will earn ($0.92) per share for the year, down from their previous estimate of $1.51. Atb Cap Markets also issued estimates for Bradmer Pharmaceuticals’ FY2026 earnings at $0.73 EPS.
Separately, Cantor Fitzgerald raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th.
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- How is Compound Interest Calculated?
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- How to Read Stock Charts for Beginners
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- Ride Out The Recession With These Dividend Kings
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
